Risk factor
Negligible price volatility
Profitability factor
Undervalued vs peers
About
China National Accord Medicines Corporation Ltd. primarily focuses on the wholesale and retail distribution of a wide array of pharmaceutical and medical products. The company's extensive product offerings include traditional Chinese remedies, advanced biochemical and biological medicines, diagnostic agents, and antibiotics. Additionally, it supplies various chemical preparations, food items, industrial chemicals, and a diverse range of other general commodities. Beyond its core sales activities, the company is involved in selling medical apparatus and instruments. It offers comprehensive logistics services, encompassing freight transportation, warehousing, and cargo handling, alongside professional consulting. Further diversifying its operations, it markets glassware, cosmetics, and daily necessities, and provides goods agency services. The firm also participates in the import and export of technology, leases properties, and engages in the wholesale and retail of health-related products. As of December 31, 2021, China National Accord Medicines managed a significant network of 8,798 drugstores across 20 provinces, autonomous regions, and municipalities within China. This expansive retail footprint included 7,257 directly owned stores and 1,541 franchised locations. Established in 2004 and based in Shenzhen, China, the company operates as a subsidiary of Sinopharm Group Co., Ltd.
Company Valuation
Based on key historical and expected multiples, the stock is undervalued relative to its peers. Specifically, the stock is 'cheap' on P/E, undervalued on EV/EBITDA, overp
Target Price
The average target price of 000028.SZ is 26.0 and suggests 28.6% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to